Welcome to his presentation of the Q4 and full year results. Fourth quarter report.
They are presented.
And all about GARD®.
We stand firm, well stocked. SenzaGen ORA® database. Thereafter. Presentation of SenzaGen Group overview now.
We will now cover the Strategic Initiatives plan from the Director of Capital Markets, and the new institutional international shareholders, following a vote in November. As Eiffel Investment Group. The report highlights strong GARD® sales. So we have the report, and so. So, in summary. Total net sales increased by 10%, which required significant effort.
We have to constantly present. We set a new record for GARD® sales at 12.3 million SEK, representing an increase of 13% (or 10% FX-adjusted), with order intake contributing an additional 10% or 5%. 60%. We maintained the stability of our financial ledger in line with SenzaGen AB's normal operational performance, and we addressed an issue. The issue from which it stemmed. So far, 57% of the product mix comes from it.
GARD® is even more central.
And so we look at reducing our Opex by six and a half percent to 76 million, bringing it under control. During the year. Consequently, this resulted in a nearly flat EBIT, down 3%, and flat earnings per share, with an EBIT of -5 million SEK. In. EBIT was a marginal result. We adhere to IFRS, which we report on here from time to time, or other international standards. Still.
Our order book was strong at the end of the year. We had a million orders. Now we go in with a six-million order book. A stark position for the outlook. And GARD®. There. Order intake, and the first sales we saw. Record for selling 10 to 12 million. We also recorded stronger direct order intake, including a half-million order from Stewart globally, and 2.5 million in global total backlog. So, in a new segment of technology. So, the 10% or 12% that we have from strategic net-new global groups, some are wondering about.
Okay. Overall, we saw that 80% of our business came from repeat customers. So we have a solid foundation. Base business, or repeat business, as an automatic order. And then 85%.
So it's a very broad, diversified customer base.
Product mix.
And later on, the overall percentage of tests completed for GARD® and some standard tests under OECD guidelines or complementary tests, resulted in a total that was a little larger but marginal. And so we sold and outsourced the tests, but also in-sourced testing again. So, whether tests come to us or are outsourced, now we see 6 to 8 GARD® tests that yield 50% repeat business. And for CROs, we have well over six examples. For. For example, ORA® is used for Clarins cosmetics from France and by BIC, a cosmetic or health-related company, as detailed on their website. So, you can find webinars on how to test for natural botanical extracts. For example, Google 'SenzaGen Clarins webinar'. For Sonova, which reports on medical technology, there are other relevant posts.
Google Scholar. Search 'SenzaGen Sonova'. So, to elaborate. Sonova screens new materials.
So. We also operate through our subsidiaries, VitroScreen and ToxHub.
We are fortunate to have a focus on discipline and VitroScreen's culture at SenzaGen. To be frank, we are at an all-time low in sales, pipeline, and sales leads within our firm and also an unfair system. We implemented GARD® capacity at VitroScreen in Milan for better efficiency in managing a consistent workload and optimizing costs from management to operational ISO levels. So we are going to proceed, and we are confident of the full effect.
Full effect for ToxHub.
Some consultants talk about fantastic fifty percent growth for groups, with sales up from 10%. We are looking to expand into new segments or niches within this industry, and through collaboration, developing a group capable of generating cross-sales with a low cost of sales, targeting 13% to four and a half million, or leveraging the portfolio of user group offerings. So. These are some highlights from the culture without sugarcoating the company and the Group.
At etc.
Our focus is for better human health.
By ensuring ethical product tests, SenzaGen Lund addresses 30% of concerns in some settings. The focus of our non-animal testing and toxicology GARD® platform.
We have a blog at VitroScreen Milano. SenzaGen performs complete ORA® effect testing on a product or substance, using its ORA® platform, an organoid test platform capable of testing the substance's effects on multiple organs. So, the technique in Milano or in some settings involves personnel, or synergies with ToxHub, with 80% of its three employees and a network of other experts, who can provide regulatory risk and toxicological screening. Genotoxicity testing so that we can. Get. The job done. And the whole shift from testing to non-animal testing was more than 6.5%. Then net sales were $13 million. We are nearing an addressable market of half a million dollars. So for groups at. All of the firms find scientific or technical biological test models and come to use a range of tests for non-animal testing, which are cost-effective. And then. And your tests go further, and are then driven. Our testing will also apply to Europa and Nordamerika, covering Kosmetika. Meditech. Kemikalier. Lakemedel. Number. Strategic initiatives for accelerating execution. Our strategic objectives and future innovations. Further initiatives are aimed at establishing GARD® as a standard Medical Device technique.
The deep dive and opening up the hood.
Allergy test. Some methods are recognized as regulatory standards or achieve the status of an international organization, such as ISO, which validates them or works to establish GARD® as a standard method. We will also validate GARD®skin Dose-Response, and we will also focus on the genomic DNA aspects of GARD® to ensure its continued advancement.
Now we are.
Initiative to accelerate. Innovation and commercial organization for expanding our market. Reach. Forward. Strategic. Strategic initiatives going forward will be paid for upon completion of our growth plan. One of our strategic initiatives focuses on medical devices.
So. Our GARD®skin Medical Device functions for an application that we have published, and we have now successfully concluded a ring trial demonstrating that GARD® performs effectively across three independent labs, yielding substantial results, and we offer a comprehensive test portfolio, including addressing some of the commonly reported significant parameters.
The demand for dose response using GARD®skin Dose-Response, where we face challenges. But one can address issues related to concentration, or measure dose response; these evaluations can also be performed on a standalone basis. So we hope to receive the initial approval from ECVAM, which is the body that recommends test methods to the OECD, and this will also enable us to expand our reach, as we are establishing a robust global presence to secure strong repeat business.
Our testing includes the Comet assay. Significant strides in building our presence at NIH or FDA for broader regulatory acceptance will go over for regulatory testing. So therefore, we also know that our distribution strategy involves American CROs, such as Eurofins USA, leveraging their ISO and scientific expertise. Clarins, BIC, Sonova, TGA. We have worked in parallel to broaden the test portfolio for completing the test or for GARD®skin.
How we implemented EpiSensA as a skin sensitization test under review by the TGA. So we can send our product to market, and we have completed and implemented the SenzaGen VitroScreenORA® model. Then some commercial interest for the VitroScreenORA® cartilage organoid model. For example, in Medical Device applications, for an initial order, and also for prospective pipeline development, we are exploring additional endpoints.
Future applications in sensitization, or substantial uses, even in genotoxicity in vitro or developmental toxicity, or using machine learning, or so-called in silico screening. So, from now. There we can break even soon. We break even with strict control.
So at ORA®. Medical device. Accelerator. Growth in the acceleration phase. Driving market reach. Efterfrågan. Tests for medical devices. ISO 10993-10. In order to achieve FDA clearance for MedTech methods, we can offer comprehensive strategies. So we see then, indicative of impact. In vivo, ex vivo, and break-even are key aspects. In vitro advantages and stronger growth force. Stronger growth for our future. We therefore can scale up the method of testing for implementation.
Ha! Eiffel Investment Group is a new institutional shareholder at SenzaGen AB. They have a strong and robust financial structure and are major international institutional investors. Eiffel Investment Group and international institutional investors.
And €12 million assets under management, with long-term investments. Sustainable investing. Focus. We are aiming for circa 100 million kronor to 400 million, some of which is allocated for long-term investment, or to achieve strong VitroScreenORA® models by 2030, and to potentially accelerate our initiatives, manage capital for the company, support and commercialize the upscaling of strategic initiatives, and expand our regulatory activities.
Our growth. Plan and break even.
Force. Acceleration phase. Eiffel Investment Group has become a major institutional shareholder. So, for our top five list. SenzaGen AB.
So, among our institutional investors, Eiffel Investment Group holds 4%, with Sonova, ShapeQ, and other commercial entities together representing a total of 6%. ShapeQ, a major institutional investor in the high-tech sector. Ålandsbanken ABP 3%. Professor Carl Borrebaeck and Laurent Inglebert, 5%. Laurent Inglebert holds 0.8% in SenzaGen AB.
At the TGA. Services for in vitro testing, or pre-clinical testing, or for regulatory clearance for a test, or for assays at SenzaGen's technical labs.
So, a warm welcome on board.
A long time to build.
Where we come from so far. We are starting strongly, and we have a record order book. Or we have a boost, or we are interested in backlog, totaling significant figures.
Oh! Oh!